Saunthararajah Y - Search Results

1

The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.

Cui S, Lim KC, Shi L, Lee M, Jearawiriyapaisarn N, Myers G, Campbell A, Harro D, Iwase S, Trievel RC, Rivers A, DeSimone J, Lavelle D, Saunthararajah Y, Engel JD. Cui S, et al. Among authors: saunthararajah y. Blood. 2015 Jul 16;126(3):386-96. doi: 10.1182/blood-2015-02-626259. Epub 2015 Jun 1. Blood. 2015. PMID: 26031919 Free PMC article.

2

A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.

Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, Verma A, Feldman EJ, Goldfinger M. Levitz D, et al. Among authors: saunthararajah y. Clin Cancer Res. 2023 Aug 1;29(15):2774-2780. doi: 10.1158/1078-0432.CCR-23-0842. Clin Cancer Res. 2023. PMID: 37341641

3

HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.

Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP, Simonis T, Molldrem J, Young NS, Barrett AJ. Saunthararajah Y, et al. Blood. 2002 Sep 1;100(5):1570-4. Blood. 2002. PMID: 12176872 Free article.

4

Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.

Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman R, DeSimone J. Saunthararajah Y, et al. Blood. 2003 Dec 1;102(12):3865-70. doi: 10.1182/blood-2003-05-1738. Epub 2003 Aug 7. Blood. 2003. PMID: 12907443 Free article. Clinical Trial.

5

Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A.

Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajah Y, Hoffman R. Milhem M, et al. Among authors: saunthararajah y. Blood. 2004 Jun 1;103(11):4102-10. doi: 10.1182/blood-2003-07-2431. Epub 2004 Feb 19. Blood. 2004. PMID: 14976039 Free article.

6

DNA hypo-methylating agents and sickle cell disease.

Saunthararajah Y, Lavelle D, DeSimone J. Saunthararajah Y, et al. Br J Haematol. 2004 Sep;126(5):629-36. doi: 10.1111/j.1365-2141.2004.05064.x. Br J Haematol. 2004. PMID: 15327513 Free article. Review.

7

Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.

Saunthararajah Y, DeSimone J. Saunthararajah Y, et al. Semin Hematol. 2004 Oct;41(4 Suppl 6):11-6. doi: 10.1053/j.seminhematol.2004.08.003. Semin Hematol. 2004. PMID: 15534852 Review.

8

Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis.

Lavelle D, Chin J, Vaitkus K, Redkar S, Phiasivongsa P, Tang C, Will R, Hankewych M, Roxas B, Singh M, Saunthararajah Y, Desimone J. Lavelle D, et al. Among authors: saunthararajah y. Am J Hematol. 2007 Nov;82(11):981-5. doi: 10.1002/ajh.21020. Am J Hematol. 2007. PMID: 17696208 Free article.

9

DNA methylation and mechanism of action of 5-azacytidine.

Lavelle D, Saunthararajah Y, Desimone J. Lavelle D, et al. Among authors: saunthararajah y. Blood. 2008 Feb 15;111(4):2485; author reply 2486. doi: 10.1182/blood-2007-10-119867. Blood. 2008. PMID: 18263785 Free article. No abstract available.

10

Clinical effectiveness of decitabine in severe sickle cell disease.

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J. Saunthararajah Y, et al. Br J Haematol. 2008 Apr;141(1):126-9. doi: 10.1111/j.1365-2141.2008.07027.x. Br J Haematol. 2008. PMID: 18324975 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters